ReviewVeterinary sciences2026
Bovine Viral Diarrhea Virus and Vaccine Protection Strategies.
Review in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Cytopathogenic BVDV Core Protein Binds with ASC-Enhance the Assembly of Inflammasome Complex and GSDMD-Mediated Pyroptosis.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bovine viral diarrhea virus (BVDV) is a critical pathogen affecting the global cattle industry, causing severe economic losses primarily through persistent infection, immunosuppression, and reproductive failure. The virus exhibits substantial genetic diversity, with marked geographic variation in circulating subtypes, which complicates effective disease control. BVDV evades host immune responses by suppressing type I interferon signaling, impairing neutrophil function, and reprogramming host cellular metabolism, ultimately leading to the generation of persistently infected (PI) animals that serve as the principal reservoir for viral transmission. Current prevention and control strategies rely mainly on the identification and elimination of PI animals in combination with vaccination. However, conventional vaccines, including inactivated vaccines (IVs) and modified live vaccines (MLVs), have notable limitations, such as suboptimal subtype matching, interference by maternal antibodies, and safety concerns associated with MLV use in pregnant cattle. Emerging vaccine platforms, including mRNA vaccines, subunit vaccines, and multi-epitope vaccines, offer promising alternatives owing to their improved safety profiles, rapid design and production, and potential to elicit broad and robust immune responses. Future BVDV vaccine development should integrate artificial intelligence-driven design strategies with high-throughput sequencing and molecular epidemiological surveillance to enable the rational development of multivalent and multi-epitope vaccines. In addition, coordinated implementation of strain monitoring, PI animal clearance, and enhanced biosecurity practices will be essential for establishing a comprehensive and sustainable BVDV prevention and control framework.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.